(Q42675525)

4 November 2017

title

Re-treatment of chronic hepatitis C with consensus interferon . (English)

1 reference

4 November 2017

1 reference

1 reference

1 reference

E J Heathcote

1

1 reference

4 November 2017

E B Keeffe

2

1 reference

4 November 2017

S S Lee

3

1 reference

4 November 2017

S V Feinman

4

1 reference

4 November 2017

M J Tong

5

1 reference

4 November 2017

K R Reddy

6

1 reference

4 November 2017

D G Albert

7

1 reference

4 November 2017

K Witt

8

1 reference

4 November 2017

L M Blatt

9

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 April 1998

1 reference

4 November 2017

1 reference

4 November 2017

volume

27

1 reference

4 November 2017

issue

4

1 reference

4 November 2017

page(s)

1136-1143

1 reference

Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Genetic organization and diversity of the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Nucleotide sequence and mutation rate of the H strain of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Therapy of Hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Interferons and their actions

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Long-term follow-up of patients with chronic hepatitis C treated with α-interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Hepatitis C virus infection and type II cryoglobulinemia: An immunological perspective

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

A proposed system for the nomenclature of hepatitis C viral genotypes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Retreatment with recombinant interferon-alpha in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Retreatment of chronic hepatitis C with interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Re-treatment of interferon-resistant patients with chronic hepatitis C with interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Differential expression of Na+,H(+)-antiporter mRNA in biliary epithelial cells and in hepatocytes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Clinical toxicity of the interferons.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Side effects of alpha interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270431

7 January 2021

Identifiers

DOI

10.1002/HEP.510270431

1 reference

4 November 2017

1 reference